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INTRODUCTION
Nephrolithiasis is one of the most common urinary diseases, 
and its prevalence has been increasing worldwide.1-4 In gener-
al, there is a consensus that the first line of treatment for pa-
tients with renal calculi of less than 20 mm is either shock wave 
lithotripsy (SWL) or retrograde intrarenal surgery (RIRS).5-7 Ac-
cording to a previous meta-analysis, the stone-free rate (SFR) 
of RIRS is higher than that of SWL; moreover, RIRS is generally 
followed by fewer retreatments than SWL.8-12 
Generally, RIRS is performed at general hospitals as it re-
quires hospitalization; at the hospital, general anesthesia is 
administered to the patient, and flexible ureteroscopy and en-
dovision system facilities are available.13 In contrast, SWL, 
routinely performed at private clinics or low-volume hospi-
tals, is preferred among patients due to its high accessibility, 
short procedural time, relatively inexpensive cost, and local 
anesthesia requirement.5,8,10,11,14-17 By examining extensive Ko-
rean claims data, Ko, et al.18 reported that SWL was frequently 
used as a method of treatment in South Korea but, due to rela-
tively low SFRs, it resulted in hospital revisits, reoperations, 
patient inconvenience, and additional economic burden.
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who had any record of treatment with modalities, including 
SWL, RIRS, and percutaneous nephrolithotomy (PCNL), with-
in 6 months before the index date were excluded from the 
analysis. 
The length of an episode to treat renal stones was defined as 
6 months, as per expert opinion. If a record of SWL, RIRS, or 
PCNL existed after the index date within an episode, the re-
cord was classified as retreatment for the same renal stone. To 
include records related to only renal stones, claims data re-
garding reimbursement for exclusively renal stones were in-
cluded [using the International Classification of Diseases, 
Tenth Revision (ICD-10) codes N-200]. The study protocol was 
reviewed by the Institutional Review Board of Gachon Univer-
sity (Approval No. 1044396-201708-HR-139-01).
Model overview
We used a decision tree model to investigate the cost-effec-
tiveness of introducing RIRS in the treatment sequence from 
the payers’ perspective in South Korea. The model was con-
structed based on a previous study,21 on the assumption that a 
maximum of four successive treatments can be performed in 
each patient. 
The treatment modalities, including SWL, RIRS, and PCNL, 
resulted in two possible outcomes: 1) “non-retreatment,” 
which probably meant a treatment success; and 2) “retreat-
ment,” which indicated a treatment failure. After the failure of 
a previous treatment, the patient was expected to advance to 
the next line of treatment. As the data obtained from insur-
ance claims do not provide information regarding the clinical 
setting, the current study used non-retreatment rate (NRR) 
rather than SFR, for the evaluation of treatment outcomes. Pi-
lot analysis showed that the percentages of patients who un-
derwent PCNL after first line SWL failure and after first line 
RIRS failure were 0.31% and 0.36%, respectively. As a cost-ef-
fectiveness model should be as simple as possible, PCNL was 
excluded from the model.22 The model is presented in Fig. 2. 
Oval shapes represent chance nodes. A chance node is a point 
where one or two alternative treatments (SWL or RIRS) are 
possible. In this study, we assumed five possible scenarios as 
follows. First, “clinic scenario” meant performing only SWL 
(maximum four times). Second, “RIRS scenario” meant per-
forming RIRS as a first line treatment and, then performing 
RIRS or SWL as subsequent treatments. Third, “early switch 
scenario” meant performing RIRS as a second line of treat-
ment after first SWL failure and, then performing RIRS or SWL 
as a subsequent treatment. Fourth, “intermediate switch sce-
nario” meant performing RIRS as the third line treatment after 
two successive SWL failures and, then performing RIRS or 
SWL as a subsequent treatment. Fifth, “late switch scenario” 
meant performing RIRS as the fourth line of treatment after 
three successive SWL failures.  
The authors assumed that the patients involved in the cur-
rent study followed any of the aforementioned scenarios. The 
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Considering that repeated SWL in private clinics and low-
volume hospitals might incur unnecessary societal burden, 
SWL should be substituted with another procedure, the SFR 
of which is higher than that of SWL. A previous study reported 
that SWL was more cost-effective than RIRS.19 However, the 
study had a considerable limitation in that it compared the ef-
fectiveness of SWL with that of RIRS in the same line of treat-
ment. In real-world clinical settings, however, diverse treat-
ment sequences and intricate treatment plans may exist. 
Therefore, we compared the clinical and economic outcomes 
between RIRS and SWL by analyzing population-based data 
and evaluated the most cost-effective line of treatment for 
RIRS in the treatment sequence. 
MATERIALS AND METHODS
Real clinical evidence generation
We analyzed the medical claims data for insurance reimburse-
ment provided by the Health Insurance Review and Assess-
ment Service (HIRA) to observe the outcomes of RIRS and 
SWL for renal stones. We then analyzed these two treatment 
modalities for their cost-effectiveness. As a public agency, 
HIRA conducts healthcare performance evaluation and deter-
mines whether or not medical claims need to be reimbursed. 
This repository of claims data covers approximately 98% of the 
Korean population and contains records of inpatient and out-
patient utilization, medication use, and other healthcare re-
source use.20 We used the claims data from July 1, 2015 to June 
30, 2017 (Fig. 1) in this study. 
Since the aim of this study was to examine the clinical out-
comes of SWL and RIRS, we only included patients who initi-
ated treatment with either SWL or RIRS. Patients who had any 
record of SWL or RIRS from January 1, 2016 to December 31, 
2016 were identified. Among the noted records for each pa-
tient, the first obtained record was selected and the date of re-
cord was defined as the index date. After defining the index 
date for each patient, we reviewed the claims data 6 months 
prior to the index date to include only incident patients. Those 
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study was based on the assumption that each patient be-
longed to one of the following five mutually exclusive sub-
groups: 1) patients who did not undergo retreatment after the 
first line of treatment; 2) patients who did not undergo retreat-
ment after the second line of treatment; 3) patients who did 
not undergo retreatment after the third line of treatment; 4) 
patients who did not undergo retreatment after the fourth line 
of treatment; and 5) patients who were not cured, even after 
four successive rounds of treatments. The expected NRR in 
each scenario was calculated by totaling the probabilities of 
belonging to any of the first four subgroups, which indicated 
the overall success rate of each scenario. The expected cost in 
each scenario was the weighted average of economic out-
comes of the five mutually exclusive subgroups, which was 
calculated by multiplying the probability of being in a sub-
group by the economic outcome of being that subgroup.
Model input
1) NRR: We defined SWL group as the group of patients who un-
derwent SWL as the first line of treatment. Likewise, RIRS group 
was defined as the group of patients who underwent RIRS as the 
first line of treatment. NRRs were calculated for each group and 
each sequence. As the model assumed a maximum of fourth 
line of treatment, we estimated NRRs up to the fourth line of 
treatment. However, the claims data lacked information about 
renal stone size and location; therefore, we had to operationally 
define “non-retreatment” for the data. If a patient had no suc-
cessive record of treatment within 6 months after the index date 
(i.e., the duration of an episode), as defined earlier, the patient 
was assumed to have undergone no further treatment. For ex-
ample, if a patient had no further record of treatment within an 
episode after the index date of performing RIRS, the patient was 
considered to be cured by first line treatment with RIRS. We as-
sumed that the NRRs of the fourth round of treatment were the 
same as those of the third, since the number of patients who un-
derwent a fourth line of treatment was too small to allow NRR 
calculation.
2) Selection probability: Selection probability was applied 
on the chance node of the decision tree model. A patient was 
assumed to move to SWL or RIRS after failure according to the 
selection probability. As the sum of selection probability was 1 
for each chance node, the selection probability of RIRS of each 
sequence was calculated by subtracting the value of SWL from 
1. Similar to NRR, selection probabilities were also calculated 
separately for SWL and RIRS groups. The probability to select 
SWL as the second line of treatment, for example, was calcu-
lated by dividing “the number of patients who received SWL 
during the second line of treatment” by “the number of pa-
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tients who underwent the second line of treatment.” Similar to 
the calculation of NRRs, we assumed that the selection proba-
bility for the fourth line of treatment was the same as that of 
the third line of treatment due to the limited sample size.
3) Cost: Costs were estimated separately according to the 
consequences and the sequence of each treatment. For exam-
ple, in case of a patient who underwent SWL as the first line of 
treatment without success and subsequently underwent the 
second line of treatment of RIRS with success, the “cost of the 
first SWL that was termed a failure” and the “cost of the RIRS 
that was a success” were calculated separately. The former was 
the sum of the cost spent from the index date to the day before 
the date of second line of RIRS, and the latter was the cost in-
curred from the date of second line of RIRS to the end of the 
episode. After estimating the cost for each patient for each se-
quence, we derived the average cost by dividing the total cost 
by the number of patients for each sequence. Similar to NRR, 
the cost incurred from the fourth line of treatment was consid-
ered the same as that for the third line due to the limited sam-
ple size. All of the costs estimated in Korean won were convert-
ed to US dollars using a conversion rate of 1100 won/US dollar.
Cost-effectiveness analysis
The expected NRRs and the expected cost of each scenario 
was calculated by running the model with inputs, as men-
tioned above. Subsequently, the outcomes of RIRS including 
scenarios were compared with the outcomes of the clinical 
scenario. We also presented an incremental cost-effectiveness 
ratio (ICER), which is a summary measure to describe the 
economic value of an intervention compared to a comparator 
that is normally a standard of care.22 Generally, ICER is calcu-
lated by dividing the incremental cost by the incremental ef-
fectiveness in a cost-effectiveness analysis. Incremental cost 
refers to the cost incurred by substituting a comparator to a 
new intervention. Incremental effectiveness means the bene-
fit derived by the substitution. In the current study, ICER was 
calculated by dividing the incremental cost by the incremen-
tal NRRs; that is, ICER indicated the monetary value per re-
treatment avoided. The clinic scenario was the comparator in 
all cost-effectiveness analysis. Therefore, the clinical and eco-
nomic outcomes of the RIRS scenario, early switch scenario, 
intermediate switch scenario, and late switch scenario were 
compared to those of the clinic scenario.
Since the cost of RIRS and SWL are constantly changing in 
Korea, deterministic sensitivity analysis was performed to 
demonstrate the impact of the aforementioned changes in 
costs. Every year, the reimbursement plan for each treatment, 
including surgeries, is published by HIRA. Considering the 
increasing trend in the charges from 2014 to 2020, the cost of 
RIRS was assumed to increase by 70 USD annually, and the 
cost of the first session of SWL treatment was assumed to in-
crease by 50 USD annually. The costs of the second, third, and 
fourth SWL treatments were assumed to rise by 30 USD annu-
ally. Probabilistic sensitivity analysis was performed to assess 
the acceptance probabilities of scenarios involving RIRS in 
the sequence compared to the clinic scenario under diverse 
willingness to pays (WTPs). In a cost-effectiveness analysis, an 
intervention was considered cost-effective if ICER was lower 
than WTP, indicating that the intervention could be accepted 
by insurers.22 Input parameters for probabilistic modeling 
were randomly selected from the means, standard errors, and 
distributions. Applying these random parameters, we ran the 
model 1000 times, which is termed as the Monte Carlo simu-
lation.22 Through probabilistic modeling, we obtained 1000 
ICERs for each comparison (e.g., RIRS scenario versus clinic 
scenario). If the 700 ICERs were under a certain WTP, the ac-
ceptance probability was considered as 70% under that WTP. 
As the standard errors for clinical outcomes could not be cal-
culated, we assumed the standard errors to be 10% of the 
means. Acceptability curves were drawn with the obtained 
acceptance probabilities. Microsoft Excel 2016 (Microsoft 
Corporation, Redmond, WA, USA) was used for all analyses.
RESULTS
Among the 11700 patients who underwent treatment for renal 
stones in South Korea from 2015 to 2017, 10590 (90.5%) pa-
tients belonged to SWL group and only 1110 (9.5%) patients 
belonged to RIRS group. Most of the patients who failed at the 
first line of SWL treatment were subsequently treated by SWL 
again (98.2%). All of the patients in RIRS group were treated in 
a hospital, whereas only 31.7% in SWL group were treated in a 
hospital (Table 1).
As shown in Table 2, the NRRs of SWL were 56% or lower, 
whereas those of RIRS ranged from 75% to 93%. The average 
cost of SWL was lower than that of RIRS in every sequence 
(Table 3). Among all sequences, the cost of RIRS as the third 
line of treatment was the highest ($3832).
On running the decision tree model with inputs derived 
from real-world data, the overall NRR in the clinic scenario 
was observed to be 0.928, whereas the overall NRRs of the 
other scenarios, including RIRS in their treatment sequences, 
were higher than that observed in the clinic scenario. The 
overall NRR was observed to increase up to 0.997, when RIRS 
was performed earlier (Table 4). The expected cost was also 
the highest in the RIRS scenario ($2692). On the contrary, the 
expected cost for each scenario decreased when RIRS was 
performed later. As a result, ICER was the lowest in the late 
switch scenario ($3377). 
Deterministic sensitivity analysis showed that the order of 
ICERs of the scenarios did not change with the change in the 
costs of RIRS and SWL (Table 4). For sensitivity analysis, the 
acceptance curve was drawn using the values detailed in Ta-
ble 5. Under varying WTPs, the late switch scenario was the 
most likely to be cost-effective, whereas the other scenarios, 
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which involved RIRS in the earlier sequence, were less likely 
to be cost-effective (Fig. 3).
DISCUSSION
Compared to the non-conclusive pattern observed in SWL, 
the NRRs of RIRS were observed to increase when RIRS was 
performed earlier. Decision analysis demonstrated that the 
expected NRR was the highest in the RIRS scenario. However, 
the expected cost in the RIRS scenario was the highest, com-
pared to those in the other scenarios. Consequently, ICER was 
the highest when the RIRS scenario was compared to the clin-
ic scenario, indicating that performing RIRS earlier was not as 
cost-effective as performing it later. As shown by the accept-
ability curve, the late switch scenario was most likely to be 
cost-effective compared with the other scenarios.
Although the SFRs of RIRS were similar to the previously re-
ported values, the SFRs of SWL derived from this study were 
lower than those obtained in previous clinical trials.11,12,23 The 
low SFRs may be due to the differences between clinical trials 
and real-world clinical settings. In clinical trials, clinicians sort 
out participants according to the predefined inclusion criteria 
to show the precise efficacy and effectiveness of a treatment.5 
However, aspects other than the inclusion criteria, such as fa-
vorable accessibility of a clinic, short operative time, patients’ 
experience, patients’ preference on non-invasive treatments, 
decision of a physician, and a quick return to everyday life, 
Table 1. Demographics of the Study Population
SWL (n=10590) RIRS (n=1110)
Sex, n (%)
Male 7086 (66.9) 659 (59.4)
Female 3504 (33.1) 451 (40.6)
Age, n (%)
<45 yr 3124 (29.5) 248 (22.3)
45–64 yr 5537 (52.3) 584 (52.6)
≥65 yr 1929 (18.2) 278 (25.1)
Health insurance type, n (%)
Health insurance 10015 (94.6) 1073 (96.7)
Other 575 (5.4) 37 (3.3)
Charlson comorbidity score, n (%)
0 8249 (77.9) 788 (71.0)
1 1969 (18.6) 237 (21.4)
2 320 (3.0) 65 (5.9)
≥3 52 (0.5) 20 (1.8)
Type of medical institution, n (%)
Clinic 7231 (68.3) 0 (0.0)
Hospital 176 (1.7) 2 (0.2)
General hospital 2044 (19.3) 278 (25.0)
Tertiary general hospital 1139 (10.8) 830 (74.8)
Outcome of the first treatment, n (%)
Non-retreatment 5493 (51.9) 1031 (92.9)
Failure 5097 (48.1) 79 (7.1)
Type of treatment after failure
SWL 5004 (98.2) 37 (46.8)
RIRS 62 (1.2) 38 (48.1)
PCNL 31 (0.6) 4 (5.1)
SWL, shock wave lithotripsy; RIRS, retrograde intrarenal surgery; PCNL, per-
cutaneous nephrolithotomy.
Table 2. Base Case Model Inputs




Second line after SWL failure 0.50
Second line after RIRS failure 0.56
Third line after first SWL failure 0.46
Third line after first RIRS failure 0.53
Fourth line after first SWL failure 0.46
Fourth line after first RIRS failure 0.53
RIRS
First line 0.93
Second line after SWL failure 0.89
Second line after RIRS failure 0.92
Third line after first SWL failure 0.88
Third line after first RIRS failure 0.75
Fourth line after first SWL failure 0.88
Fourth line after first RIRS failure 0.75
Selection probability†
Second line SWL after RIRS failure 0.49
Third line SWL after two SWL failure 0.99
Third line SWL after first line SWL, second line RIRS failure 0.71
Third line SWL after first line RIRS, second line SWL failure 0.88
Third line SWL after two RIRS failure 0.33
Costs (USD)‡
Cost of first SWL (non-retreatment) 840
Cost of first SWL (failure) 748
Cost of first RIRS (non-retreatment) 2555
Cost of first RIRS (failure) 2534
Cost of second SWL (non-retreatment) 540
Cost of second SWL (failure) 431
Cost of second RIRS (non-retreatment) 2400
Cost of second RIRS (failure) 2315
Cost of third SWL (non-retreatment) 492
Cost of third SWL (failure) 1508
Cost of third RIRS (non-retreatment) 2313
Cost of third RIRS (failure) 3832
SWL, shock wave lithotripsy; RIRS, retrograde intrarenal surgery.
*The non-retreatment rate or cost of fourth line of treatment was the same 
as the non-retreatment rate or cost of third line of treatment, †The selection 
probability of RIRS in each treatment sequence was calculated by subtract-
ing the value of SWL from 1, ‡The cost in Korean won were converted to US 
dollars using the conversion rate of 1100 won/US dollar.
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Table 3. Input Parameters for Deterministic Sensitivity Analyses
Input parameters
Cost (USD)
Base value 1 year later 2 years later
Cost of first SWL (non-retreatment) 840 890 940
Cost of first SWL (failure) 748 798 848
Cost of first RIRS (non-retreatment) 2555 2625 2695
Cost of first RIRS (failure) 2534 2604 2674
Cost of second SWL (non-retreatment) 540 570 600
Cost of second SWL (failure) 431 461 491
Cost of second RIRS (non-retreatment) 2400 2470 2540
Cost of second RIRS (failure) 2315 2385 2455
Cost of third SWL (non-retreatment) 492 522 552
Cost of third SWL (failure) 1508 1538 1568
Cost of third RIRS (non-retreatment) 2313 2383 2453
Cost of third RIRS (failure) 3832 3902 3972
SWL, shock wave lithotripsy; RIRS, retrograde intrarenal surgery.
Table 4. Results of Decision Analyses





Incremental cost (USD) Incremental NRRs ICER
Base case
Clinic scenario (reference) 1420 0.928 - - -
RIRS scenario 2692 0.997 1272 0.068 18640
Early switch scenario 2060 0.990 640 0.062 10376
Intermediate switch scenario 1662 0.985 242 0.056 4294
Late switch scenario 1610 0.985 190 0.056 3377
1 year later
Clinic scenario (reference) 1496 0.928 - - -
RIRS scenario 2766 0.997 1271 0.068 18624
Early switch scenario 2147 0.990 652 0.062 10559
Intermediate switch scenario 1745 0.985 249 0.056 4411
Late switch scenario 1691 0.985 195 0.056 3470
2 years later
Clinic scenario (reference) 1571 0.928 - - -
RIRS scenario 2841 0.997 1270 0.068 18609
Early switch scenario 2234 0.990 663 0.062 10742
Intermediate switch scenario 1827 0.985 255 0.056 4528
Late switch scenario 1772 0.985 201 0.056 3564
RIRS, retrograde intrarenal surgery; NRR, non-retreatment rate; ICER, incremental cost-effectiveness ratio.
may affect the NRRs of SWL.15-17,24,25 Also, in a real-world clini-
cal setting, SWL can be performed in patients with renal 
stones that are larger than 20 mm, which deviates significantly 
from the guidelines.5 However, in the current study, both 
treatments of SWL and RIRS were analyzed with the same as-
sumption; therefore, the NRRs of SWL and RIRS derived from 
this study can be considered as a reliable basis for the evalua-
tion of cost-effectiveness of each treatment sequence at the 
population level. Moreover, the objective of this study was to 
analyze and validate the cost-effectiveness of performing 
RIRS in a real-world clinical setting. Therefore, determining 
ICER using real-world values was a meaningful strategy.
Based on the results of the current study, RIRS was the best 
treatment option to reduce treatment failure. Additionally, we 
observed that the expected NRR in the intermediate switch 
scenario was not significantly different from that of the late 
switch scenario, suggesting that the benefits of performing 
RIRS gets maximized when performed earlier in the sequence. 
Therefore, RIRS should be performed as early as possible to re-
duce retreatment at the population level. Despite the benefits 
of performing RIRS as described above, insurers cannot force 
physicians to perform RIRS for many reasons. First, RIRS can-
not be performed at the level of private clinics due to the lack 
of infrastructure, which was demonstrated in the results of our 
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study that RIRS was generally performed at the hospital lev-
el.14,26 Second, before performing RIRS in real clinical settings, 
the size, location, and density of the stone should be evaluated 
and documented, as these characteristics may impact the 
treatment outcomes.5,9,10,12 Early RIRS selection can be justified 
only if the related complications and the fitness for anesthesia 
and hospitalization are favorable for performing RIRS.15-17 
Thus, even if the guidelines indicate that RIRS can be per-
formed on a patient, in case of patients who are at high risk of 
anesthesia or are afraid of ureteral stent and urethral catheter, 
SWL can be performed as an alternative. Therefore, insurers 
should detail their reimbursement plan to encourage treat-
ment with RIRS at an early stage for only eligible patients. 
According to the results of our decision analysis, performing 
RIRS earlier on in the sequence led to higher expected costs. The 
negative effect of RIRS on the economic outcome was also 
shown by the acceptability curve, such that the RIRS scenario 
was less likely to be accepted than the late switch scenario under 
the same WTP. However, the expected cost was the cheapest in 
the clinic scenario. The cost of repeated SWL was lower due to 
the reimbursement policy in South Korea, which allows up to 
50% discounted cost for subsequent SWL treatment. Our results 
from deterministic sensitivity analysis showed that even when 
the costs of treatments change, the order of ICER does not 
change. In real-world clinical settings, the entire population 
consists of the five scenarios that we assumed in this study. That 
is, some follow the RIRS scenario, whereas some follow the late 
switch scenario. Therefore, performing RIRS as the first line of 
treatment would be affordable at the population level, only if the 
patients who are eligible for RIRS follow the RIRS scenario. As 
the likelihood of performing RIRS at an earlier stage increases, 
the overall NRR and the total cost at the population level will 
also increase. Insurers should comprehensively consider the 
treatment accessibility, patient preference, and budget con-
straints to establish a new healthcare policy that would improve 
the health and economic outcomes at the population level. In 
addition, they should limit reimbursements in cases of repeated 
SWL that are not clinically indicated, and include a mandatory 
clause for the documentation of size, density, and location of the 
renal stone, before conducting any procedure. 
This study had several limitations, as the data obtained from 
the insurance claims did not include the patients’ social and 
physical conditions or details about the renal stones. As a re-
sult, it was not possible to reach conclusions regarding which 
patients should undergo RIRS at an early stage, based on the 
results of the present study. We believe that currently, treat-
ment in accordance with the established guidelines is the most 
evidence-based. This study assumed a treatment to be suc-
cessful when there were no records of further treatment. The 
aforementioned assumption and definition of a successful 
treatment may lead to bias, considering the actual clinical set-
tings; in fact, even if some patients have remnant stones, fol-
low-up observations may often be conducted for more than 6 
months. However, the length of each episode (i.e., 6 months) 
Table 5. Input Parameters for Probabilistic Sensitivity Analyses
Parameters Base value Standard error of the mean Distribution
Non-retreatment rate
SWL
First line 0.52 0.05* Beta
Second line after SWL failure 0.50 0.05* Beta
Third line after initial SWL failure 0.46 0.05* Beta
RIRS
First line 0.93 0.09* Beta
Costs (USD)
Cost of first SWL (non-retreatment) 840 7 Gamma
Cost of first RIRS (non-retreatment) 2555 32 Gamma
Cost of second SWL (non-retreatment) 540 13 Gamma
Cost of second RIRS (non-retreatment) 2400 204 Gamma
SWL, shock wave lithotripsy; RIRS, retrograde intrarenal surgery.
*Assumed to be 10% of the mean. 
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was sufficient to detect stone remission. According to the Eu-
ropean Association of Urology (EAU) guidelines, patients with 
kidney stones usually need repetitive follow-ups to deal with 
the infection and associated pain until the problematic stones 
are resolved.5 Also, if the situation does not warrant any treat-
ment, the physician should follow up with the patient after 6 
months, and then annually. Furthermore, the current study 
found that 90.8% of the patients who received SWL as the first 
line treatment presented with successful outcomes within 6 
months after the index date. The mean time interval between 
the first SWL session and the first session of retreatment was 
21.41 days, and the mean time interval between the first and 
second sessions of retreatment was 22 days, which indicates 
that the majority of treatments were done in the first 2 months 
after the index date. Meanwhile, among the 1110 patients who 
received RIRS as the first line of treatment, 99.0% presented 
with successful outcomes within 6 months. The mean of time 
interval between RIRS and first retreatment was 49.84 days, 
and the mean of time interval between the first and second re-
treatments was 56.47 days, which indicates that the majority of 
treatments, subsequent to the first RIRS, were done in the first 
3 months after the index date. Therefore, we believed that the 
time interval was sufficient to detect the majority of cases of 
recurrent stones or retreatments that occur in the real world. 
Lastly, renal stone patients may also have ureteral stones or re-
nal stones that exist in the other side of the kidneys. To over-
come this limitation, we excluded the patients with a diagnos-
tic code of ureteral stones, and only included the ones with 
renal stone disease (ICD-10 code, N200). 
Our study is the first to incorporate real clinical values into 
decision modeling to examine the cost-effectiveness of intro-
ducing RIRS into the treatment sequence of renal stone dis-
ease. We traced all possible treatment sequences to estimate 
the values of parameters, such as NRRs, selection probability, 
and cost spent on each sequence, based on large claims data. 
We also conducted a sensitivity analysis to show the accept-
ability curve of each scenario involving RIRS on its sequence, 
compared to the clinic scenario under diverse WTPs. Al-
though the reimbursement policy may differ by country, we 
believe that our findings would be useful for insurers around 
the world. Insurers should consider the clinical and financial 
impact of RIRS in advance, so that they can use our model to 
calculate ICER, which would be helpful in planning health-
care budget and revising patient reimbursement policy.
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5. Türk C, Petřík A, Sarica K, Seitz C, Skolarikos A, Straub M, et al. 
EAU guidelines on interventional treatment for urolithiasis. Eur 
Urol 2016;69:475-82. 
6. Donaldson JF, Lardas M, Scrimgeour D, Stewart F, MacLennan S, 
Lam TB, et al. Systematic review and meta-analysis of the clinical 
effectiveness of shock wave lithotripsy, retrograde intrarenal sur-
gery, and percutaneous nephrolithotomy for lower-pole renal 
stones. Eur Urol 2015;67:612-6.
7. Chang KD, Lee JY, Park SY, Kang DH, Lee HH, Cho KS. Impact of 
pretreatment hydronephrosis on the success rate of shock wave 
lithotripsy in patients with ureteral stone. Yonsei Med J 2017;58: 
1000-5.
8. Manzoor S, Hashmi AH, Sohail MA, Mahar F, Bhatti S, Khuhro 
AQ. Extracorporeal shock wave lithotripsy (ESWL) vs. ureterore-
noscopic (URS) manipulation in proximal ureteric stone. J Coll 
Physicians Surg Pak 2013;23:726-30.
9. Lawler AC, Ghiraldi EM, Tong C, Friedlander JI. Extracorporeal 
shock wave therapy: current perspectives and future directions. 
Curr Urol Rep 2017;18:25.
10. Perez Castro E, Osther PJ, Jinga V, Razvi H, Stravodimos KG, 
Parikh K, et al. Differences in ureteroscopic stone treatment and 
outcomes for distal, mid-, proximal, or multiple ureteral loca-
tions: the Clinical Research Office of the Endourological Society 
523
So-Young Yang, et al.
https://doi.org/10.3349/ymj.2020.61.6.515
ureteroscopy global study. Eur Urol 2014;66:102-9. 
11. Zhang W, Zhou T, Wu T, Gao X, Peng Y, Xu C, et al. Retrograde in-
trarenal surgery versus percutaneous nephrolithotomy versus ex-
tracorporeal shockwave lithotripsy for treatment of lower pole re-
nal stones: a meta-analysis and systematic review. J Endourol 
2015;29:745-59. 
12. Zheng C, Yang H, Luo J, Xiong B, Wang H, Jiang Q. Extracorporeal 
shock wave lithotripsy versus retrograde intrarenal surgery for 
treatment for renal stones 1-2 cm: a meta-analysis. Urolithiasis 
2015;43:549-56.
13. Jeong JY, Kim JC, Kang DH, Lee JY. Digital videoscopic retrograde 
intrarenal surgeries for renal stones: time-to-maximal stone 
length ratio analysis. Yonsei Med J 2018;59:303-9.
14. Ergin G, Kirac M, Kopru B, Ebiloglu T, Kibar Y, Biri H. Shock wave 
lithotripsy or retrograde intrarenal surgery: which one is more ef-
fective for 10-20-mm renal stones in children. Ir J Med Sci 2018; 
187:1121-6.
15. Rassweiler J, Rassweiler MC, Klein J. New technology in ureteros-
copy and percutaneous nephrolithotomy. Curr Opin Urol 2016; 
26:95-106.
16. Sarkissian C, Noble M, Li J, Monga M. Patient decision making for 
asymptomatic renal calculi: balancing benefit and risk. Urology 
2013;81:236-40.
17. Fann CY, Huang PC, Yen AM, Chen HH. Patient utility measure-
ment for managing ureteral stones: a modified standard gamble 
approach. Value Health Reg Issues 2012;1:87-92. 
18. Ko WJ, Jung JH, Han HH, Hong JH. Analysis of the status and treat-
ment pattern of patients with urinary tract stone [accessed on 2018 
January 3]. Available at: http://www.alio.go.kr/informationRe-
searchView.do?seq=2285039. 
19. Tarazona VC, Alba AB, de Pablos JAD, Mateu PB, Vivas-Consuelo 
D. Cost-effectiveness analysis of extracorporeal shock wave litho-
tripsy versus retrograde intrarenal surgery in the management of 
small moderated-sized renal stones. Value Health 2017;20:A490.
20. Kim JA, Yoon S, Kim LY, Kim DS. Towards actualizing the value 
potential of Korea Health Insurance Review and Assessment 
(HIRA) data as a resource for health research: strengths, limita-
tions, applications, and strategies for optimal use of HIRA data. J 
Korean Med Sci 2017;32:718-28.
21. Cone EB, Pareek G, Ursiny M, Eisner B. Cost-effectiveness com-
parison of ureteral calculi treated with ureteroscopic laser litho-
tripsy versus shockwave lithotripsy. World J Urol 2017;35:161-6. 
22. Briggs A, Sculpher M, Claxton K. Decision modelling for health 
economic evaluation. New York: Oxford University Press; 2006.
23. Wu CF, Shee JJ, Lin WY, Lin CL, Chen CS. Comparison between 
extracorporeal shock wave lithotripsy and semirigid ureteroreno-
scope with holmium: YAG laser lithotripsy for treating large prox-
imal ureteral stones. J Urol 2004;172:1899-902.
24. Childs MA, Rangel LJ, Lingeman JE, Krambeck AE. Factors influ-
encing urologist treatment preference in surgical management of 
stone disease. Urology 2012;79:996-1003.
25. Kuo RL, Aslan P, Abrahamse PH, Matchar DB, Preminger GM. In-
corporation of patient preferences in the treatment of upper uri-
nary tract calculi: a decision analytical view. J Urol 1999;162:1913-8.
26. Bozzini G, Verze P, Arcaniolo D, Dal Piaz O, Buffi NM, Guazzoni 
G, et al. A prospective randomized comparison among SWL, 
PCNL and RIRS for lower calyceal stones less than 2 cm: a multi-
center experience. A better understanding on the treatment op-
tions for lower pole stones. World J Urol 2017;35:1967-75.
